|Bid||204.00 x 900|
|Ask||206.00 x 900|
|Day's Range||198.32 - 229.95|
|52 Week Range||6.77 - 331.68|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||281.25|
Novavax (NASDAQ: NVAX) has completed enrollment in its late-stage study of COVID-19 vaccine NVX-CoV2373 that's being conducted in the U.S. and Mexico. In this Motley Fool Live video recorded on Feb. 24, 2021, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not there are any yellow flags with Novavax's COVID-19 vaccine trial so far. Keith Speights: We have a question about Novavax's vaccine technology.
Shares in Mabion, a Polish biotechnology company, jumped by over 60% on Wednesday morning after it announced a framework cooperation deal with U.S. vaccine developer Novavax on COVID-19 vaccination technology. "We look forward to a close cooperation with Novavax, which may pave the way for commercial scale production, provided that technology transfer and technical batch are successfully completed", Mabion Chief executive Dirk Kreder said in a statement. Under the terms of the agreement, Mabion and Novavax will work together to transfer technology for the production of a technical batch of NVX-CoV2373.
The company missed analyst estimates with its Q4 results and didn't have a firm date for filing for authorization of its COVID vaccine.